FLT3-ITD gene mutation has been reported to be a strong factor in newly diagnosed AML patients with normal cytogenetics and an independent prognostic factor that influences the treatment outcomes, overall survival and disease free survival. This evidence concerns the gene FLT3 and acute myeloid leukemia.